Alvotech Overview

  • Founded
  • 2013
Founded
  • Status
  • Private
  • Employees
  • 523
Employees
  • Latest Deal Type
  • PIPE
  • (Announced)
  • Financing Rounds
  • 5
  • Investments
  • 3

Alvotech General Information

Description

Developer and manufacturer of biogeneric products dedicated to becoming one of the leaders in the biosimilar monoclonal antibody market. The company is a specialist in biopharmaceutical product creation, all along the value chain from cell line development to commercial manufacturing with in-house R&D capabilities and fully integrated clinical and regulatory function, allowing a smooth transition from development through global launch and commercial manufacturing, thereby transforming patients' lives by improving access to affordable biosimilar medicines and enhancing the sustainability of healthcare systems.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Private Equity-Backed
Primary Industry
Biotechnology
Primary Office
  • Sæmundargata 15-19
  • Reykjavik, 101
  • Iceland
+354 522 0000

Alvotech Timeline

2019202020212022
Financing RoundFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Alvotech Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Alvotech‘s full profile, request access.

Request a free trial

Alvotech Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer and manufacturer of biogeneric products dedicated to becoming one of the leaders in the biosimilar monoclonal
Biotechnology
Reykjavik, Iceland
523 As of 2021
00000
000000000 00000

0000000

equat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla
0000000000000
Leiden, Netherlands
000 As of 0000
0000 0000-00-00
000000&0

00000000

e eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui offici
0000000000000
Planegg, Germany
000 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Alvotech Competitors (21)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Batavia Biosciences Corporation Leiden, Netherlands 000 000000&0
000000000 Formerly PE-Backed Planegg, Germany 000 00000 000000000 00000
00000000 Formerly VC-backed Germantown, MD 000 00000 000000000 00000
0000000 0000000000 Formerly VC-backed Redwood City, CA 000 00000 000000000 00000
00000000 Venture Capital-Backed San Carlos, CA 00 00000 00000000000 00000
You’re viewing 5 of 21 competitors. Get the full list »

Alvotech Patents

Alvotech Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2020244106-A1 Aqueous formulations of tnf-alpha antibodies in high concentrations Pending 18-Mar-2019 0000000000
CA-3076423-A1 Pharmaceutical formulations for adalimumab Pending 20-Sep-2017 0000000000
AU-2020102677-A4 Pharmaceutical formulations for adalimumab Active 20-Sep-2017 0000000000
AU-2020102677-B4 Pharmaceutical formulations for adalimumab Active 20-Sep-2017 0000000000
US-20210070850-A1 Pharmaceutical formulations for adalimumab Pending 20-Sep-2017 C07K16/241
To view Alvotech’s complete patent history, request access »

Alvotech Executive Team (14)

Name Title Board Seat Contact Info
Mark Levick Ph.D Chief Executive Officer
Joel Morales Chief Financial Officer
Sean Gaskell Chief Technology Officer
Rakel Ottarsdottir Chief Information Officer
Joseph McClellan Ph.D Chief Scientific Officer
You’re viewing 5 of 14 executive team members. Get the full list »

Alvotech Board Members (1)

Name Representing Role Since
000000 0000000 Self Founder & Chairman 000 0000
To view Alvotech’s complete board members history, request access »

Alvotech Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Alvotech Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Alvotech‘s full profile, request access.

Request a free trial

Alvotech Investments & Acquisitions (3)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000 00000 07-Dec-2021 0000000000 Special Purpose Acquisition Company (SPAC) 000000 00
0000 01-Mar-2019 00000 0000 00000 Pharmaceuticals
Alvotech Germany 18-May-2016 Merger/Acquisition Biotechnology
To view Alvotech’s complete investments and acquisitions history, request access »